Immune Checkpoint Inhibitor-Related Cardiovascular Toxicity in Lung Cancer: Is Routine Screening Indicated?
JACC CardioOncol
.
2019 Dec 17;1(2):193-195.
doi: 10.1016/j.jaccao.2019.11.014.
eCollection 2019 Dec.
Authors
Lova Sun
1
,
Charu Aggarwal
1
,
Roger B Cohen
1
Affiliation
1
Department of Medicine, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
PMID:
34396182
PMCID:
PMC8352329
DOI:
10.1016/j.jaccao.2019.11.014
No abstract available
Keywords:
biomarkers; cardiotoxicity; immune checkpoint inhibitors; lung cancer; monitoring.
Publication types
Editorial
Grants and funding
T32 CA009679/CA/NCI NIH HHS/United States